11th June, 2026

(1) BSE Ltd.
Listing Department
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai 400 001
Scrip Code: 500087

(2) National Stock Exchange of India Ltd.
Listing Department
Exchange Plaza, 5th floor
Plot no. C/1, G Block
Bandra Kurla Complex
Bandra (East), Mumbai - 400 051
Scrip Symbol: CIPLA EQ

(3) SOCIETE DE LA BOURSE DE LUXEMBERG
Societe Anonyme
35A Boulevard Joseph II
L-1840 Luxembourg

Sub: USFDA inspection at Company's manufacturing facility in Verna, Goa, India

Dear Sir/Madam,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and further to our intimation dated 17th April, 2026, regarding the routine current Good Manufacturing Practices (cGMP) inspection and a Pre-Approval Inspection (PAI) at Company's manufacturing facility in Verna, Goa, India between 6th to 17th April 2026, we hereby notify that the United States Food and Drug Administration (USFDA) vide communication dated 10th June 2026 (2217 hours IST) has classified the above referred inspection as Voluntary Action Indicated (VAI).

Kindly take the above information on record.

Thanking you,

Yours faithfully,
For **Cipla Limited**

RAJENDRA CHOPRA
Digitally signed by RAJENDRA CHOPRA
Date: 2026.06.11 13:46:43 +05'30'

Rajendra Chopra
Company Secretary

Prepared by: Chirag Hotchandani